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Abstract  
Diabetes mellitus more often called diabetes is a chronic condition that raises levels of 
glucose in the blood because the body cannot produce any or enough of the hormone insulin or 
use insulin effectively. When left untreated, high levels of glucose in the blood continue and 
cause damage to various body organs, leading to the development of disabling and life-
threatening health complications. Unfortunately, no cure has been found for diabetes at this 
moment. However, these serious complications can be prevented or delayed with appropriate 
management. Current methods of insulin delivery require multiple daily injections or continuous 
subcutaneous insulin infusions, causing a delay in insulin absorption and possibly creating an 
infection. These disadvantages can be solved with an implanted device. However, only 
implantable insulin devices introduced required a large battery inside the body. The purpose of 
this research is to design an implantable insulin pump that is small and uses untethered control 
through the ferromagnetic soft material actuator and magnetic field generator for control. This 
device consists of a balloon, ferromagnetic soft material, two check valves, and an insulin 
reservoir. Externally, the battery-powered magnetic field will be created to deform ferromagnetic 
soft material and squeeze the balloon to inject insulin. The ferromagnetic soft material is 
fabricated and magnetized for controlled deformation, by controlling balloon deformation with 
an accurate external magnetic field, precise insulin injection is possible without any of the 
discomfort that current insulin delivery devices give. In this research, the major objectives are to 
design of battery-less implantable insulin pump using a ferromagnetic soft material, create a 
profile between the magnetic field and fluid flow, construction of system and test for its accuracy 
and precision. Finally, test data will be compared with the FEM simulation date. This will show 
the feasibility of this implantable insulin pump design 
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Chapter 1: Introduction 
1.1 Background 
Diabetes mellitus more often called diabetes is a chronic condition that raises levels of 
glucose in the blood because the body cannot produce any or enough of the hormone insulin or 
use insulin effectively [1]. Insulin is an essential hormone produced in the pancreas which allows 
your body to turn glucose into energy called glycogen. Glucose is the primary energy source in 
the body for muscle and organs. It is the smallest of sugar that is broken down from 
carbohydrates after consumption for better transportation in the body. Glycogen is another form 
of sugar that is better suited for storage in the liver and muscles easily. These two forms of 
carbohydrate are constantly shifting in the body to maintain the energy required. During meal 
time, the body contains more glucose than it requires so insulin is produced to convert it to 
glycogen and between the meal time glucagon is produced to reverse the process.  
 
Figure 1. Cycle of Carbohydrate in the Body 
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For diabetes patients, this process is not properly working in their body and stays at high 
glucose levels more than the body can stand. When this is left untreated and high levels of 
glucose in the blood continues over the long term, it can cause damage to various body organs, 
leading to the development of disabling and life-threatening health complications like heart 
disease, stroke, kidney damage, nerve damage, blindness, and amputations of the legs and feet 
[2]. CDC, Centers for Disease Control and Prevention has reported diabetes as the seventh 
leading cause of deaths with 80,058 deaths in the United States in 2016 [3].  
 
Figure 2. Number of Death for Leading Cause of Death in 2016 
 
Additionally, the population of diabetes has been increasing in the US. CDC also reported 
that it was estimated that more than 30 million US population had it in 2015 which matches the 
diabetes population prediction made in 2009 as shown in figure 3. 
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Figure 3. Projected Diabetes Population from 2009 
Diabetes is also a significant problem to the society in the form of higher medical costs, 
decreased productivity, early mortality, and low quality of life. The estimated economic burden 
due to diabetes in the United States in 2012 was $327 billion [4].  
 
Figure 4. The Cost of Diabetes 
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Not all diabetes is the same for every patient. When looked deeper into diabetes, there are 
mainly two types of diabetes, type 1 and type 2 diabetes. Type 1 diabetes is caused by the body’s 
immune system attacking the insulin-producing beta cells in the pancreas, resulting in the 
inability to create insulin [1]. Type 2 diabetes, which is around 90% of all cases of diabetes, is 
due to the body’s insufficient production of insulin and resistance of the insulin produced from 
the body [1]. A most important part of managing both types of diabetes patients is to maintain 
optimal levels of glucose in the blood which is between 70~150mgdl [5]. To accomplish this, a 
constant monitor of levels of glucose and accurate injection of the insulin is required. To deliver 
insulin into the bloodstream, the injection system is required. If too much insulin is injected and 
the glucose level goes below the optimal level, which creates hypoglycemia. Multiple studies are 
being conducted to create a cure for diabetes using gen modifications and other methods. 
Unfortunately, at this moment, there is no cure for diabetes. However, these serious 
complications can be prevented or delayed with appropriate management. Among different 
management, the most important one is the injection of insulin to the body to maintain the 
optimal level of glucose in the blood. 
 
1.2 Current Insulin Injection Method 
Currently, there is various insulin injection method available to patients in the market. The 
most common methods are using a syringe, insulin pen, and insulin pump. These methods use 
subcutaneous injection. The main advantage of the syringe and insulin pen is its affordability 
compared to other methods. However, cons weights over the pros as patients are responsible for 
accurate injection. It requires a series of training and preparation, an injection can be painful 
when done inaccurately, rotation of injection site, subcutaneous injection creates time lag for 
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insulin to travel to the bloodstream. Lastly, patients need to use active glucose measurement is 
required to find the exact insulin amount to inject.  
Another method is using an insulin pump. It solved a lot of complications that the syringe 
and insulin pen had by eliminating training, preparation, pain from the injection, and other 
complications. The reason this was possible is through continuous glucose monitor (CGM) 
which can constantly track glucose level in the blood and send the data to the insulin pump to 
calculate the accurate amount of insulin and automatically inject through injection port as shown 
in figure 5. This allows diabetic patients to forget about the injection and have a more flexible 
diet. This helps patients to feel less like the patient and have a more active life which helps to 
mitigate diabetes.  For these reasons, an insulin pump is currently the closest method to mimic 
the pancreas in the market.  
 
Figure 5. Schematics of Insulin Pump 
However, even insulin pumps still cannot solve the problem of the time lag of insulin 
absorption, risk of skin infection at the injection port, and liphohypertrophy, a condition from 
injecting insulin at one site for a long period of time causing lump filled with extra fat to rise. 
Additionally, having a large pumping device on the waist with a constant open injection port 
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makes patients be less active. The insulin pump is also a very expensive device costing more 
than $6,000. 
 
Figure 6. Liphohypertrophy 
1.3 Implantable Insulin Pump 
To solve the time lag of insulin absorption and the risk of a skin infection, a more direct 
injection method called intraperitoneal (IP) infusion is introduced. IP infusion injects a substance 
into the peritoneum, a body cavity to be absorbed via the capillaries. By using IP infusion, 
insulin can be delivered directly to the liver which follows the path of naturally produced insulin 
from the pancreas. Many case studies show faster absorption speed compared to subcutaneous 
injection and better control of glucose level in blood. 
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Figure 7. Intraperitoneal (IP) Infusion 
Unfortunately, as IP infusion method requires deeper penetration, constant external injection 
method like insulin pump becomes too risky with possible penetration of diseases. Therefore, 
different means of insulin pump had to introduce for internal injection. And this is why an 
implantable insulin pump (IIP) is presented. IIP also is known as an artificial pancreas, is an 
insulin pumping device implanted to the body with an insulin reservoir that can be externally 
refilled. There have been several IIP types of research and development promotion but only one 
product has made it to the market. Dr. Christopher Saudek from John Hopkin’s Diabetes Center 
implanted the first MiniMed implantable insulin pump in 1986.  
 
Figure 8. Schematics of MiniMed Implantable Insulin Pump 
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Figure 9. Photo of MiniMed Implantable Insulin Pump 
However, the device did not last long. In 2007 Medtronic purchased MiniMed and stopped 
the research trials in the United States [6]. The reasoning behind the discontinuation is from too 
many complications of the system. The main complication was from the battery inside the 
implanted device. At the time, the battery was not efficient enough for long time use and easily 
failed even before the predicted life of the pump. Additionally, having a battery itself is 
dangerous due to its enormous amounts of energy in a small volume and is surrounded by several 
hazardous materials [5]. Implanting such an energy source in the inner body, a special space 
filled with electrical, chemical, mechanical, and marine-salted reactions, can unstabilize the 
battery quickly [6]. As a result, many patients went through additional surgery for replacement. 
This is why even though many case studies show MiniMed IIP performance better in 
maintaining the glucose level in the blood and multiple patients’ testimony of improved lifestyle, 
Medtronic discontinued the device.  
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Figure 10. Surgical Process of MiniMed Implantable Insulin Pump 
Even though the MiniMed IIP was not successful, the improved result it showed in 
maintaining the optimal glucose level in blood is undeniable. Therefore, it is necessary to 
develop an implantable insulin pump that can overcome the complication that MiniMed IIP had 
and this can be achieved by removing the battery from the implanting pump system. 
  
1.4 Significance of Research 
Removing the battery from the pump system means that the pump needs to operate 
wirelessly. When looking at the forces in nature, the magnetic force is the one that can achieve 
this and materials that react to the magnetic force are called ferromagnetic materials that exhibit 
strong magnetism in the same direction of the field, when a magnetic field is applied to it. 
However, these materials are solids that make it heavy and difficult to implement with other 
systems. This is where the idea of ferromagnetic soft material can be used. By mixing soft 
materials like polymer and ferromagnetic materials in powder form with directionality given, it is 
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possible to achieve flexible material that can be controlled with a magnetic field. With this, a 
simple but effective mechanical pump can be designed.  
As seen in figure 11, the pump system consists of a balloon, actuator made of 
ferromagnetic soft material, two check valves, and an insulin reservoir. Two one-way valves are 
placed on each side of the balloon to block any reverse flow, the Actuator is placed on top of the 
balloon, and the reservoir is connected to the balloon. Externally, a battery-powered magnetic 
field generator will be placed on top of where the pump system is located. This way when the 
magnetic field is generated, it will deform the actuator which will squeeze the balloon to inject 
insulin. Next, when the magnetic field is turned off, the actuator will come back to the original 
shape and the balloon will inflate again with insulin from the reservoir.  
 
Figure 11: Schematics of New Implantable Insulin Pump 
In this research, the major objectives are to design of battery-less implantable insulin 
pump using a ferromagnetic soft material, create a profile between the magnetic field and fluid 
flow, construction of system and test for its accuracy and precision. Finally, test data will be 
compared with the FEM simulation data. This will show the feasibility of this implantable 
insulin pump design. 
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Chapter 2: Methodology 
2.1 Fabrication of Ferromagnetic Soft Material  
 As previously mentioned, ferromagnetic soft material is a mixture of soft material like 
polymer with ferromagnetic materials in powder form. In this study, polydimethylsiloxane 
(PDMS) was mixed with neodymium iron boron alloy powder (NdFeB). One interesting feature 
of polymer is the ability to obtain different material properties by varying the ratio of mixture 
between the NdFeB powder, PDMS base, and curing agent. For this study, 20% NdFeB with a 
20:1 ratio of base to an agent for PDMS was used. To create this ferromagnetic soft material, 
first, a calculation is required to obtain the weight of each material. Next, each material is poured 
into a container after weighing. Then, for the thorough mixing process, the container is placed in 
the centrifuge machine. This mixture is then poured on to mold as demonstrated in figure 12. 
Two different mold shape is needed for this step, one is for the actual actuator with a dimension 
of 14mm x 10mm x 2mm and another for the tensile test as seen in figure 13 and 14. Once 
placed on the mold PDMS takes about 20 hours to cure and harden. This process can be 
accelerated by placing the mixture in the oven with 80.  
 
Figure 12: Molding, Fabrication method of Ferromagnetic Soft Material Mold 
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Figure 13: Ferromagnetic Soft Material for Actuator 
 
Figure 14: Ferromagnetic Soft Material for Tensile Test 
 
2.2 Tensile Test 
 Once the material is cured, the tensile test is conducted to find the material properties. 
For material model, uniaxial extension - Incompressible Neo-Hookean solid, a hyperelastic 
material model was chosen to represent nonlinear stress-strain behavior. Next, from the test 
machine, the stress-strain data is collected. This data is imported to the MATLAB where 
coefficient, is calculated using curve fitting application with the neo-Hookean material equation. 
After conducting three tests, averaging the value was obtained. Using the equation below, shear 
modulus, and elastic modulus is calculated for this ferromagnetic soft material. 




𝑆ℎ𝑒𝑎𝑟 𝑀𝑜𝑑𝑢𝑙𝑢𝑠, 𝐺 = 2 ∗ 𝐶1 
𝐸𝑙𝑎𝑠𝑡𝑖𝑐 𝑀𝑜𝑑𝑢𝑙𝑢𝑠, 𝐸 = 2𝐺(1 + 𝑣) 
For incompressible material, v = 0.5 
𝐸 = 3𝐺 
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2.3 Magnetization 
 With ferromagnetic soft material molded for the actuator, magnetization is conducted to 
give magnetic directionality. Initially, when the ferromagnetic soft material is cured, iron 
particles start at the lowest energy state where the magnetic domain is random. However, the 
magnetic domain is not fixed in place. Under the strong external magnetic field, the domain 
walls will move by the process of the spins of the electrons in atoms near the wall in one domain 
turning under the influence of the external field to face in the same direction as the electrons in 
the other domain, thus reorienting the domains as seen in figure 15. Additionally, the domains 
will remain aligned when the external field is removed, creating a magnetic field of their own 
extending into the space around the material, thus creating a "permanent" magnet. The domains 
do not go back to their original minimum energy configuration when the field is removed 
because the domain walls tend to become pinned to the defects in the crystal lattice, maintaining 
their parallel orientation. 
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2.4 Magnetic Field & Deflection 
Once the magnetization on the actuator is completed, a test on deflection under a 
magnetic field can be conducted. First, the magnetic field is measured at each increment of 
voltage supply from 0V to 15V as shown in figure 16. Then, the actuator is placed on the center 
of the magnetic field generator to measure the deflection.  To verify, the simulation was 
conducted with fixed one end and load at the other end representing the magnetic force on a 
beam. 
 
Figure 16: Magnetic Field Measurement 
  
Figure 17: Actuator Deflection Measurement and Simulation 
   
 









0 0 0.00 
1 0.7 1.06 
3 4 4.55 
5 7.8 7.32 
7 11.3 8.94 
9 15.1 10.13 
11 19.3 11.01 
13 23.6 11.70 
15 26 12.04 
Table 1: Magnetic Field and Deflection Measurement  
 
Figure 18: Displacement vs. Magnetic Field Plot 
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2.5 Force & Volume Change  
 The next test setup is for the fluid flow which mimics the implanted environment. Setup 
is constructed as shown in Figures 19 and 20. The pump system is unattached with a magnetic 
field generator by a 2mm layer of acrylic just like the implanted pump system would be 
separated by the skin. From this test setup, the volume of fluid pushed through the pump is 
measured by measuring the length of the tube traveled by the fluid and multiplied the area for 
volume. 
 
Figure 19. Schematics of Fluid Flow Test Setup 
 
Figure 20. Photo of Actual Test Setup 
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In the simulation, two material, actuator and balloon are introduced. The actuator used material 
property obtained from the tensile test and balloon use material property of thermoplastic 
polyurethane elastomer which had Young’s Modulus, E = 13.1MPa with Poisson’s ratio, v = 0.5 for 
incompressible solid. Then, fix boundary condition was given to the left end of the actuator and bottom 
of the balloon as seen in figure 21. Constant pressure was given inside the balloon to represent the fluid 
pressure. Lastly, displacement instead of force was given to the right end of the actuator for better 
convergence. Equivalent force to displacement is found by the reaction force. Once the simulation was 
completed, the volume of flow is obtained by converting the deformed balloon in the STL file and 
measure the volume with MATLAB volume command and subtracting it from the original volume.  
 
 
Figure 21: Image of Fluid Flow Boundary Condition and Simulation Result 
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Figure 22 shows a plot of simulation data for volume change with an increase of force 
exerted on the actuator. By utilizing the magnetic field – force relationship obtained in the 
previous step, data is converted to volume change with an increase of the magnetic field. Finally, 
an exponential trend line representing the characteristic of this pump design is obtained using 
curve fitting application in MATLAB and shown in figure 23. Lastly, two sets of test data are 
compared with simulation data in figure 24. It is shown that simulation and test match in the 
small magnetic field, but difference increases as the magnitude of the magnetic field increases. 
This is due to errors in the balloon from the test setup where the balloon does not always start at 
a fully inflated state. 
𝑦 =  𝑎 ∗ 𝑒𝑥𝑝(𝑏 ∗ 𝑥) − 𝑎 
𝑎 =      0.7504 
𝑏 =      0.1243 
 
Figure 22: Force vs. Volume Change Plot  
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Figure 23: Magnetic Field vs. Volume Change Plot with Trend Line 
 
 
Figure 24: Magnetic Field vs. Volume Change with Test data 
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Chapter 3: Conclusion & Future Work 
3.1 Conclusion 
To conclude, a battery-less implantable insulin pump using ferromagnetic soft material 
that can be affordable and help diabetes patients glucose level in blood is designed and tested 
along with FEM simulation and was able to obtain a profile between the magnetic field and fluid 
flow. Even though this profile is unique for this design, the ability to create a different profile 
that matches the need shows room for improvement. This research has successfully demonstrated 
the feasibility of an implantable insulin pump without any battery or electronics. Lastly, a 
prototype was designed and fabricated as shown in Figures 25 and 26.  
 
Figure 25: Prototype Design 
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Figure 26: Prototype Fabrication 
3.2 Future Work 
For future work, to complete this implantable insulin pump system, the design of the 
portable battery-powered uniform magnetic field generator is needed. Additionally, animal 
testing through coordination with the medical company and further investigation on ways to 
minimize the design size using smaller components will help this implantable insulin pump 
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